Resmetirom Market

“Resmetirom Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Resmetirom for Liver fibrosis in the 7MM. A detailed picture of the Resmetirom for Liver fibrosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Resmetirom for Liver fibrosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Resmetirom market forecast, analysis for Liver fibrosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Liver fibrosis.

Drug Summary

Madrigal’s most advanced clinical candidate, resmetirom, is a once-daily, oral, thyroid hormone receptor (THR) ß-selective agonist designed specifically to treat the underlying causes of NASH in the liver while improving multiple atherogenic lipid profiles.

Thyroid hormone receptors can be classified as a receptors and ß receptors, and activating the a receptor results in all of the symptoms associated with too much thyroid gland activity. On the other hand, thyroid hormone receptor ß agonism affects metabolic processes by lowering serum lipids such as low-density lipoprotein (LDL) cholesterol, serum triglycerides, and other metabolic factors. There is a possibility that these changes could lower liver fat and reduce the toxicity of fat in the liver of patients with non-alcoholic fatty liver disease (NAFLD). Thus, by engaging the thyroid ß receptor, the patient does not experience symptoms of thyrotoxicosis or the toxic effect of the thyroid hormone, which is mediated through the a receptor. Essentially, this drug's primary mechanism of action suggests potentially improving the patient’s lipid profile and hepatic fat.

Resmetirom is currently being studied in Phase III trials. It is designed to target the underlying causes of NASH by reducing or eliminating liver fat (steatosis) as well as reducing liver inflammation, liver cell ballooning (hepatocyte cell death), and liver fibrosis that can lead to cirrhosis. Phase III and Phase II clinical data support the potential for resmetirom to become the first-to-market therapy for NASH patients with liver fibrosis.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Resmetirom description, mechanism of action, dosage and administration, research and development activities in Liver fibrosis.
• Elaborated details on Resmetirom regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Resmetirom research and development activity in Liver fibrosis in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Resmetirom.
• The report contains forecasted sales of Resmetirom for Liver fibrosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Liver fibrosis.
• The report also features the SWOT analysis with analyst views for Resmetirom in Liver fibrosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Resmetirom Analytical Perspective by DelveInsight

In-depth Resmetirom Market Assessment

This report provides a detailed market assessment of Resmetirom in Liver fibrosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Resmetirom Clinical Assessment

The report provides the clinical trials information of Resmetirom in Liver fibrosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Liver fibrosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Resmetirom dominance.
• Other emerging products for Liver fibrosis are expected to give tough market competition to Resmetirom and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Resmetirom in Liver fibrosis.
• Our in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Resmetirom in Liver fibrosis.

Key Questions

• What is the product type, route of administration and mechanism of action of Resmetirom?
• What is the clinical trial status of the study related to Resmetirom in Liver fibrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Resmetirom development?
• What are the key designations that have been granted to Resmetirom for Liver fibrosis?
• What is the forecasted market scenario of Resmetirom for Liver fibrosis?
• What are the forecasted sales of Resmetirom in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Liver fibrosis and how are they giving competition to Resmetirom for Liver fibrosis?
• Which are the late-stage emerging therapies under development for the treatment of Liver fibrosis?